To include your compound in the COVID-19 Resource Center, submit it here.

Tazemetostat: Phase II started

Epizyme began an open-label, international Phase II trial to evaluate 800 mg oral tazemetostat twice daily in about 90 adult patients. The

Read the full 223 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE